Minimizing the Risks of Anticoagulants and Platelet Inhibitors

被引：28

作者：

Alexander, Karen P. ^{[1
]}

Peterson, Eric D. ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Dept Med, Duke Clin Res Inst, Durham, NC 27715 USA

来源：

CIRCULATION | 2010年 / 121卷 / 17期

基金：

美国医疗保健研究与质量局;

关键词：

anticoagulants; platelet inhibitors; risk management; ACUTE CORONARY SYNDROMES; ACUTE MYOCARDIAL-INFARCTION; ASPIRIN-TREATED PATIENTS; UNFRACTIONATED HEPARIN; ST-ELEVATION; BLEEDING COMPLICATIONS; ANTIPLATELET THERAPY; GENETIC-DETERMINANTS; ANTITHROMBIN THERAPY; PRIMARY ANGIOPLASTY;

D O I：

10.1161/CIRCULATIONAHA.109.853135

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1960 / 1970

页数：11

共 112 条

[1] Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures - Systematic overview and meta-analysis of randomized trials [J].

Agostoni, P ;

Biondi-Zoccai, GGL ;

De Benedictis, ML ;

Rigattieri, S ;

Turri, M ;

Anselmi, M ;

Vassanelli, C ;

Zardini, P ;

Louvard, Y ;

Hamon, M .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (02) :349-356

[2] Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes [J].

Alexander, KP ;

Chen, AY ;

Roe, MT ;

Newby, LK ;

Gibson, CM ;

Allen-LaPointe, NM ;

Pollack, C ;

Gibler, WB ;

Ohman, EM ;

Peterson, ED .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (24) :3108-3116

[3]

[Anonymous], 2001, COCHRANE DATABASE SY

[4] Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial [J].

Aronow, Herbert D. ;

Steinhubl, Steven R. ;

Brennan, Danielle M. ;

Berger, Peter B. ;

Topol, Eric J. .

AMERICAN HEART JOURNAL, 2009, 157 (02) :369-374

[5]

Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161

[6]

Bazzino O, 1998, NEW ENGL J MED, V338, P1498

[7]

Bazzino O, 1998, NEW ENGL J MED, V338, P1488

[8] Nucleic acid aptamers in therapeutic anticoagulation - Technology, development and clinical application [J].

Becker, RC ;

Rusconi, C ;

Sullenger, B .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (06) :1014-1020

[9] Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study [J].

Becker, Richard C. ;

Moliterno, David J. ;

Jennings, Lisa K. ;

Pieper, Karen S. ;

Pei, Jinglan ;

Niederman, Alan ;

Ziada, Khaled M. ;

Berman, Gail ;

Strony, John ;

Joseph, Diane ;

Mahaffey, Kenneth W. ;

Van de Werf, Frans ;

Veltri, Enrico ;

Harrington, Robert A. .

LANCET, 2009, 373 (9667) :919-928

[10] Unfractionated heparin, low molecular weight heparins, and pentasaccharide: Basic mechanism of actions, pharmacology, and clinical use [J].

Bick, RL ;

Frenkel, EP ;

Walenga, J ;

Fareed, J ;

Hoppensteadt, DA .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2005, 19 (01) :1-+

← 1 2 3 4 5 6 7 8 9 10 →